Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/28/2015)... The global mHealth market ... by 2020, growing at a CAGR of 47.6% from ... Grand View Research, Inc. Monitoring services is expected to ... to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... incidences of chronic diseases such as cancer, heart ailments, ...
(Date:8/27/2015)... 27, 2015 DURECT Corporation (Nasdaq: DRRX ... at three upcoming healthcare conferences.  , ... present at the Rodman & Renshaw Investment Conference on ... conference is being held at the St. Regis Hotel ... live audio webcast of the presentation will be available ...
(Date:8/27/2015)... India , August 27, 2015 According ... Product (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, ... - Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling ... USD 411.5 Million in 2015, at a CAGR of 11.4 % ... 136 ma rket data T ables and ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Pharmaceuticals, Inc. (Nasdaq: ALXA ), today announced that ... warrants to purchase shares of its common stock in an ... sole book-running manager in the offering. The ... no assurance as to whether or when the offering may ...
... Wash., Feb. 16, 2012  SCOLR Pharma, Inc. (OTCQB: SCLR) ... nutritional/vitamin products based on the Company,s patented oral drug delivery ... Eleven class-leading products are now being sold under various ... top retail chains.  Each product has ...
Cached Medicine Technology:Alexza Announces Proposed Public Offering of Common Stock and Warrants 2Alexza Announces Proposed Public Offering of Common Stock and Warrants 3Alexza Announces Proposed Public Offering of Common Stock and Warrants 4SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012 2
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... On ... the Mesothelioma Applied Research Foundation (Meso Foundation) will present an educational program ... at 7:00 PM and lasts through 9:30 PM (doors open at 6:45pm) at Calvary ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Brands like ... with zero standard shipping costs. , “Before, a threshold of $49.00 was required to ... brands and items qualify for free standard shipping for customers regardless of the item’s ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
(Date:8/28/2015)... ... 2015 , ... Approximately 2,000 United Methodists are expected to ... children, a thank you to the many creative and generous ways in which ... Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium event, ...
(Date:8/28/2015)... Church, VA (PRWEB) , ... ... ... Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and Best ... Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... The Jewish Home has named Nitin Nanda, M.D., ... Dr. Nanda will also serve as medical director of ... the Home,s Joyce Eisenberg-Keefer Medical Center on the Grancell ... positions, Dr. Nanda will be responsible for the supervision ...
... of Georgia is part of a large national study ... 10,000 healthy individuals in an effort to pinpoint variations ... samples taken from each group will enable a sophisticated ... convey individual risk for the disease that affects about ...
... Md., April 27 Patients with stone disease could ... University of California, San Francisco suggests that ... may be sufficient to inhibit the development of calcium ... Scientific Meeting of the American Urological Association (AUA). Increased ...
... nurses and doctors utilizing expert Geriatric Doctors, the Assistant Director of ... save the medical industry potentially, $200 Billion annually. , ... ... announces a tremendous saving in lives and medical costs of ...
... 27 Estill Medical Technologies, Inc., the industry leader ... the expansion of its Thermal Angel sales and marketing ... by quickly controlling core body temperature and infection risk. ... In emergency medicine, the golden hour refers to the ...
... drugstore.com , inc. (Nasdaq: DSCM ... and pharmacy products, today announced that they have reached ... sales and use taxes owed by the Company for ... )The Company has paid an aggregate of approximately $1.7 ...
Cached Medicine News:Health News:New Chief of Geriatric Psychiatry and Behavioral Health is Announced 2Health News:MCG participating in national study to identify genetic variants in schizophrenia 2Health News:MCG participating in national study to identify genetic variants in schizophrenia 3Health News:Drinking Diet Soda May Reduce the Risk of Forming Kidney Stones 2Health News:Medical Nurse Training, Inc. Announces New Techniques to Achieve Tremendous Savings of Lives and Medical Costs of Over $200 Billion Annually 2Health News:Thermal Angel Supports Infection Control During the Golden Hour 2Health News:drugstore.com, inc. Resolves New Jersey Sales and Use Tax Case 2
... designed with the proper sensitivity and specificity ... of autoimmune disease. Sera from over 2,000 ... individuals were tested during the development of ... compared the results to reference methods such ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... are formed as a host defense against ... phagocytosis. If not cleared, CIC may be ... CIC are increased in Systemic Lupus Erythematosus ... involved in other autoimmune disorders as well ...
The K-ASSAY® D-Dimer Control set is intended to be used a consistent test sample of known concentration for monitoring the performance of D-Dimer immunoturbidimetric assays....
Medicine Products: